α cgrp Search Results


cgrp  (Rockland Immunochemicals)
85
Rockland Immunochemicals cgrp
Cgrp, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B1+cgrp/pmc04560334-182-75-77?v=Rockland+Immunochemicals
Average 85 stars, based on 1 article reviews
cgrp - by Bioz Stars, 2026-08
85/100 stars
  Buy from Supplier
human αcgrp  (Tocris)
92
Tocris human αcgrp
Human αcgrp, supplied by Tocris, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B1+cgrp/pm33149301-345-37-40?v=Tocris
Average 92 stars, based on 1 article reviews
human αcgrp - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier
human α cgrp  (Tocris)
90
Tocris human α cgrp
Human α Cgrp, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B1+cgrp/pmc08424805-63-9-14?v=Tocris
Average 90 stars, based on 1 article reviews
human α cgrp - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
cgrp elisa kit  (Boster Bio)
94
Boster Bio cgrp elisa kit
(A) Schematics of the experiment. Rag1 -/- female mice received daily subcutaneous injections of low-dose IL-2 (30,000 I.U.) or PBS for 4 weeks, 4 weeks after ovariectomy or sham operation. (B) Representative 3D μCT images of the distal femurs. (C) Quantification of μCT images by BV/TV (bone volume per tissue volume), Tb.N (trabecular number), Tb.Sp (trabecular separation), and Tb.Th (trabecular thickness), n=7-10 per group, bar indicates mean, one-way ANOVA, ∗P<0.05, ∗∗P<0.01. (D) Representative histological images of bone sections stained with H&E (top), TRAP (middle), and anti-TRAP immunohistochemistry (bottom) to evaluate the abundance of osteoclasts on bone surface. (E) UMAP visualization of bone marrow innate lymphoid cell (ILC) subsets from scRNA-seq data (Left) with key genes identifying ILC2s and ILC1s/ILC3s subclusters (Right). (F) Split UMAP visualization showing the distribution of bone marrow ILCs in each treatment group. (G) Pie charts showing the ratio of ILC2s to ILC1s/ILC3s. (H-I) Representative flow cytometry plots (H) and the quantification of BM-ILC2s (Lin - CD45 + CD127 + ST2 + Sca-1 + ) in WT and Rag1 -/- mice (I) . (J) Volcano plot of bulk RNA-seq data from purified ILC2s showing differential expression between control and IL-2 treated groups. (K) GO Pathway enrichment analysis of ILC2s comparing OVX vs. OVX + IL-2 groups from scRNA-seq data. (L-M) FACS sorted bone marrow CD3 - B220 - NK1.1 - CD11b + cells and ILC2s (Lin - CD45 + CD127 + Sca-1 + ST2 + ) from WT, Il10 -/- , <t>Calca</t> -/- and Il10 -/- Calca -/- (DKO) were cocultured at indicated ratios, in the presence of 20 ng/ml M-CSF and 50 ng/ml RANKL. Osteoclast formation was evaluated by TRAP staining. Representative images (L) and quantification (M) of TRAP + multinucleated (nuclei > 3) cells. Representative of at least 3 independent experiments. Bar indicates mean, one-way ANOVA, ∗∗P<0.01, ∗∗∗P<0.001, ∗∗∗∗P<0.0001. (N) Flow cytometry analysis of peripheral blood ILC2s in healthy donors (n=27) compared to patients with osteoporosis (n=17). T-test, ∗P<0.05. (O) Pearson correlation analysis between ILC2s and clinical samples with available BMD T-score, n=24, black indicates healthy donor, red indicates osteoporosis patients.
Cgrp Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B1+cgrp/bio_rxiv__64898__2026__01__07__696511-210-19-22?v=Boster+Bio
Average 94 stars, based on 1 article reviews
cgrp elisa kit - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier
cgrp  (Shanghai Korain Biotech Co Ltd)
92
Shanghai Korain Biotech Co Ltd cgrp
(A) Schematics of the experiment. Rag1 -/- female mice received daily subcutaneous injections of low-dose IL-2 (30,000 I.U.) or PBS for 4 weeks, 4 weeks after ovariectomy or sham operation. (B) Representative 3D μCT images of the distal femurs. (C) Quantification of μCT images by BV/TV (bone volume per tissue volume), Tb.N (trabecular number), Tb.Sp (trabecular separation), and Tb.Th (trabecular thickness), n=7-10 per group, bar indicates mean, one-way ANOVA, ∗P<0.05, ∗∗P<0.01. (D) Representative histological images of bone sections stained with H&E (top), TRAP (middle), and anti-TRAP immunohistochemistry (bottom) to evaluate the abundance of osteoclasts on bone surface. (E) UMAP visualization of bone marrow innate lymphoid cell (ILC) subsets from scRNA-seq data (Left) with key genes identifying ILC2s and ILC1s/ILC3s subclusters (Right). (F) Split UMAP visualization showing the distribution of bone marrow ILCs in each treatment group. (G) Pie charts showing the ratio of ILC2s to ILC1s/ILC3s. (H-I) Representative flow cytometry plots (H) and the quantification of BM-ILC2s (Lin - CD45 + CD127 + ST2 + Sca-1 + ) in WT and Rag1 -/- mice (I) . (J) Volcano plot of bulk RNA-seq data from purified ILC2s showing differential expression between control and IL-2 treated groups. (K) GO Pathway enrichment analysis of ILC2s comparing OVX vs. OVX + IL-2 groups from scRNA-seq data. (L-M) FACS sorted bone marrow CD3 - B220 - NK1.1 - CD11b + cells and ILC2s (Lin - CD45 + CD127 + Sca-1 + ST2 + ) from WT, Il10 -/- , <t>Calca</t> -/- and Il10 -/- Calca -/- (DKO) were cocultured at indicated ratios, in the presence of 20 ng/ml M-CSF and 50 ng/ml RANKL. Osteoclast formation was evaluated by TRAP staining. Representative images (L) and quantification (M) of TRAP + multinucleated (nuclei > 3) cells. Representative of at least 3 independent experiments. Bar indicates mean, one-way ANOVA, ∗∗P<0.01, ∗∗∗P<0.001, ∗∗∗∗P<0.0001. (N) Flow cytometry analysis of peripheral blood ILC2s in healthy donors (n=27) compared to patients with osteoporosis (n=17). T-test, ∗P<0.05. (O) Pearson correlation analysis between ILC2s and clinical samples with available BMD T-score, n=24, black indicates healthy donor, red indicates osteoporosis patients.
Cgrp, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B1+cgrp/pm37596867-51-28-37?v=Shanghai+Korain+Biotech+Co+Ltd
Average 92 stars, based on 1 article reviews
cgrp - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier
αcgrp primary antibody  (ABclonal Biotechnology)
90
ABclonal Biotechnology αcgrp primary antibody
(A) Schematics of the experiment. Rag1 -/- female mice received daily subcutaneous injections of low-dose IL-2 (30,000 I.U.) or PBS for 4 weeks, 4 weeks after ovariectomy or sham operation. (B) Representative 3D μCT images of the distal femurs. (C) Quantification of μCT images by BV/TV (bone volume per tissue volume), Tb.N (trabecular number), Tb.Sp (trabecular separation), and Tb.Th (trabecular thickness), n=7-10 per group, bar indicates mean, one-way ANOVA, ∗P<0.05, ∗∗P<0.01. (D) Representative histological images of bone sections stained with H&E (top), TRAP (middle), and anti-TRAP immunohistochemistry (bottom) to evaluate the abundance of osteoclasts on bone surface. (E) UMAP visualization of bone marrow innate lymphoid cell (ILC) subsets from scRNA-seq data (Left) with key genes identifying ILC2s and ILC1s/ILC3s subclusters (Right). (F) Split UMAP visualization showing the distribution of bone marrow ILCs in each treatment group. (G) Pie charts showing the ratio of ILC2s to ILC1s/ILC3s. (H-I) Representative flow cytometry plots (H) and the quantification of BM-ILC2s (Lin - CD45 + CD127 + ST2 + Sca-1 + ) in WT and Rag1 -/- mice (I) . (J) Volcano plot of bulk RNA-seq data from purified ILC2s showing differential expression between control and IL-2 treated groups. (K) GO Pathway enrichment analysis of ILC2s comparing OVX vs. OVX + IL-2 groups from scRNA-seq data. (L-M) FACS sorted bone marrow CD3 - B220 - NK1.1 - CD11b + cells and ILC2s (Lin - CD45 + CD127 + Sca-1 + ST2 + ) from WT, Il10 -/- , <t>Calca</t> -/- and Il10 -/- Calca -/- (DKO) were cocultured at indicated ratios, in the presence of 20 ng/ml M-CSF and 50 ng/ml RANKL. Osteoclast formation was evaluated by TRAP staining. Representative images (L) and quantification (M) of TRAP + multinucleated (nuclei > 3) cells. Representative of at least 3 independent experiments. Bar indicates mean, one-way ANOVA, ∗∗P<0.01, ∗∗∗P<0.001, ∗∗∗∗P<0.0001. (N) Flow cytometry analysis of peripheral blood ILC2s in healthy donors (n=27) compared to patients with osteoporosis (n=17). T-test, ∗P<0.05. (O) Pearson correlation analysis between ILC2s and clinical samples with available BMD T-score, n=24, black indicates healthy donor, red indicates osteoporosis patients.
αcgrp Primary Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B1+cgrp/pm37231189-73-43-45?v=ABclonal+Biotechnology
Average 90 stars, based on 1 article reviews
αcgrp primary antibody - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
rabbit primary antibodies to cgrp  (Bachem)
90
Bachem rabbit primary antibodies to cgrp
(A) Schematics of the experiment. Rag1 -/- female mice received daily subcutaneous injections of low-dose IL-2 (30,000 I.U.) or PBS for 4 weeks, 4 weeks after ovariectomy or sham operation. (B) Representative 3D μCT images of the distal femurs. (C) Quantification of μCT images by BV/TV (bone volume per tissue volume), Tb.N (trabecular number), Tb.Sp (trabecular separation), and Tb.Th (trabecular thickness), n=7-10 per group, bar indicates mean, one-way ANOVA, ∗P<0.05, ∗∗P<0.01. (D) Representative histological images of bone sections stained with H&E (top), TRAP (middle), and anti-TRAP immunohistochemistry (bottom) to evaluate the abundance of osteoclasts on bone surface. (E) UMAP visualization of bone marrow innate lymphoid cell (ILC) subsets from scRNA-seq data (Left) with key genes identifying ILC2s and ILC1s/ILC3s subclusters (Right). (F) Split UMAP visualization showing the distribution of bone marrow ILCs in each treatment group. (G) Pie charts showing the ratio of ILC2s to ILC1s/ILC3s. (H-I) Representative flow cytometry plots (H) and the quantification of BM-ILC2s (Lin - CD45 + CD127 + ST2 + Sca-1 + ) in WT and Rag1 -/- mice (I) . (J) Volcano plot of bulk RNA-seq data from purified ILC2s showing differential expression between control and IL-2 treated groups. (K) GO Pathway enrichment analysis of ILC2s comparing OVX vs. OVX + IL-2 groups from scRNA-seq data. (L-M) FACS sorted bone marrow CD3 - B220 - NK1.1 - CD11b + cells and ILC2s (Lin - CD45 + CD127 + Sca-1 + ST2 + ) from WT, Il10 -/- , <t>Calca</t> -/- and Il10 -/- Calca -/- (DKO) were cocultured at indicated ratios, in the presence of 20 ng/ml M-CSF and 50 ng/ml RANKL. Osteoclast formation was evaluated by TRAP staining. Representative images (L) and quantification (M) of TRAP + multinucleated (nuclei > 3) cells. Representative of at least 3 independent experiments. Bar indicates mean, one-way ANOVA, ∗∗P<0.01, ∗∗∗P<0.001, ∗∗∗∗P<0.0001. (N) Flow cytometry analysis of peripheral blood ILC2s in healthy donors (n=27) compared to patients with osteoporosis (n=17). T-test, ∗P<0.05. (O) Pearson correlation analysis between ILC2s and clinical samples with available BMD T-score, n=24, black indicates healthy donor, red indicates osteoporosis patients.
Rabbit Primary Antibodies To Cgrp, supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B1+cgrp/pmc04523525-123-4-11?v=Bachem
Average 90 stars, based on 1 article reviews
rabbit primary antibodies to cgrp - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
cgrp antibody sheep  (Biomol GmbH)
90
Biomol GmbH cgrp antibody sheep
(A) Schematics of the experiment. Rag1 -/- female mice received daily subcutaneous injections of low-dose IL-2 (30,000 I.U.) or PBS for 4 weeks, 4 weeks after ovariectomy or sham operation. (B) Representative 3D μCT images of the distal femurs. (C) Quantification of μCT images by BV/TV (bone volume per tissue volume), Tb.N (trabecular number), Tb.Sp (trabecular separation), and Tb.Th (trabecular thickness), n=7-10 per group, bar indicates mean, one-way ANOVA, ∗P<0.05, ∗∗P<0.01. (D) Representative histological images of bone sections stained with H&E (top), TRAP (middle), and anti-TRAP immunohistochemistry (bottom) to evaluate the abundance of osteoclasts on bone surface. (E) UMAP visualization of bone marrow innate lymphoid cell (ILC) subsets from scRNA-seq data (Left) with key genes identifying ILC2s and ILC1s/ILC3s subclusters (Right). (F) Split UMAP visualization showing the distribution of bone marrow ILCs in each treatment group. (G) Pie charts showing the ratio of ILC2s to ILC1s/ILC3s. (H-I) Representative flow cytometry plots (H) and the quantification of BM-ILC2s (Lin - CD45 + CD127 + ST2 + Sca-1 + ) in WT and Rag1 -/- mice (I) . (J) Volcano plot of bulk RNA-seq data from purified ILC2s showing differential expression between control and IL-2 treated groups. (K) GO Pathway enrichment analysis of ILC2s comparing OVX vs. OVX + IL-2 groups from scRNA-seq data. (L-M) FACS sorted bone marrow CD3 - B220 - NK1.1 - CD11b + cells and ILC2s (Lin - CD45 + CD127 + Sca-1 + ST2 + ) from WT, Il10 -/- , <t>Calca</t> -/- and Il10 -/- Calca -/- (DKO) were cocultured at indicated ratios, in the presence of 20 ng/ml M-CSF and 50 ng/ml RANKL. Osteoclast formation was evaluated by TRAP staining. Representative images (L) and quantification (M) of TRAP + multinucleated (nuclei > 3) cells. Representative of at least 3 independent experiments. Bar indicates mean, one-way ANOVA, ∗∗P<0.01, ∗∗∗P<0.001, ∗∗∗∗P<0.0001. (N) Flow cytometry analysis of peripheral blood ILC2s in healthy donors (n=27) compared to patients with osteoporosis (n=17). T-test, ∗P<0.05. (O) Pearson correlation analysis between ILC2s and clinical samples with available BMD T-score, n=24, black indicates healthy donor, red indicates osteoporosis patients.
Cgrp Antibody Sheep, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B1+cgrp/10__1523_slash_jneurosci__4053___08__2008-60-13-18?v=Biomol+GmbH
Average 90 stars, based on 1 article reviews
cgrp antibody sheep - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
cgrp antibody  (Merck KGaA)
90
Merck KGaA cgrp antibody
(A) Schematics of the experiment. Rag1 -/- female mice received daily subcutaneous injections of low-dose IL-2 (30,000 I.U.) or PBS for 4 weeks, 4 weeks after ovariectomy or sham operation. (B) Representative 3D μCT images of the distal femurs. (C) Quantification of μCT images by BV/TV (bone volume per tissue volume), Tb.N (trabecular number), Tb.Sp (trabecular separation), and Tb.Th (trabecular thickness), n=7-10 per group, bar indicates mean, one-way ANOVA, ∗P<0.05, ∗∗P<0.01. (D) Representative histological images of bone sections stained with H&E (top), TRAP (middle), and anti-TRAP immunohistochemistry (bottom) to evaluate the abundance of osteoclasts on bone surface. (E) UMAP visualization of bone marrow innate lymphoid cell (ILC) subsets from scRNA-seq data (Left) with key genes identifying ILC2s and ILC1s/ILC3s subclusters (Right). (F) Split UMAP visualization showing the distribution of bone marrow ILCs in each treatment group. (G) Pie charts showing the ratio of ILC2s to ILC1s/ILC3s. (H-I) Representative flow cytometry plots (H) and the quantification of BM-ILC2s (Lin - CD45 + CD127 + ST2 + Sca-1 + ) in WT and Rag1 -/- mice (I) . (J) Volcano plot of bulk RNA-seq data from purified ILC2s showing differential expression between control and IL-2 treated groups. (K) GO Pathway enrichment analysis of ILC2s comparing OVX vs. OVX + IL-2 groups from scRNA-seq data. (L-M) FACS sorted bone marrow CD3 - B220 - NK1.1 - CD11b + cells and ILC2s (Lin - CD45 + CD127 + Sca-1 + ST2 + ) from WT, Il10 -/- , <t>Calca</t> -/- and Il10 -/- Calca -/- (DKO) were cocultured at indicated ratios, in the presence of 20 ng/ml M-CSF and 50 ng/ml RANKL. Osteoclast formation was evaluated by TRAP staining. Representative images (L) and quantification (M) of TRAP + multinucleated (nuclei > 3) cells. Representative of at least 3 independent experiments. Bar indicates mean, one-way ANOVA, ∗∗P<0.01, ∗∗∗P<0.001, ∗∗∗∗P<0.0001. (N) Flow cytometry analysis of peripheral blood ILC2s in healthy donors (n=27) compared to patients with osteoporosis (n=17). T-test, ∗P<0.05. (O) Pearson correlation analysis between ILC2s and clinical samples with available BMD T-score, n=24, black indicates healthy donor, red indicates osteoporosis patients.
Cgrp Antibody, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B1+cgrp/pm29813107-70-17-19?v=Merck+KGaA
Average 90 stars, based on 1 article reviews
cgrp antibody - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
rabbit anti-cgrp-a 24112  (ImmunoStar inc)
90
ImmunoStar inc rabbit anti-cgrp-a 24112
(A) Schematics of the experiment. Rag1 -/- female mice received daily subcutaneous injections of low-dose IL-2 (30,000 I.U.) or PBS for 4 weeks, 4 weeks after ovariectomy or sham operation. (B) Representative 3D μCT images of the distal femurs. (C) Quantification of μCT images by BV/TV (bone volume per tissue volume), Tb.N (trabecular number), Tb.Sp (trabecular separation), and Tb.Th (trabecular thickness), n=7-10 per group, bar indicates mean, one-way ANOVA, ∗P<0.05, ∗∗P<0.01. (D) Representative histological images of bone sections stained with H&E (top), TRAP (middle), and anti-TRAP immunohistochemistry (bottom) to evaluate the abundance of osteoclasts on bone surface. (E) UMAP visualization of bone marrow innate lymphoid cell (ILC) subsets from scRNA-seq data (Left) with key genes identifying ILC2s and ILC1s/ILC3s subclusters (Right). (F) Split UMAP visualization showing the distribution of bone marrow ILCs in each treatment group. (G) Pie charts showing the ratio of ILC2s to ILC1s/ILC3s. (H-I) Representative flow cytometry plots (H) and the quantification of BM-ILC2s (Lin - CD45 + CD127 + ST2 + Sca-1 + ) in WT and Rag1 -/- mice (I) . (J) Volcano plot of bulk RNA-seq data from purified ILC2s showing differential expression between control and IL-2 treated groups. (K) GO Pathway enrichment analysis of ILC2s comparing OVX vs. OVX + IL-2 groups from scRNA-seq data. (L-M) FACS sorted bone marrow CD3 - B220 - NK1.1 - CD11b + cells and ILC2s (Lin - CD45 + CD127 + Sca-1 + ST2 + ) from WT, Il10 -/- , <t>Calca</t> -/- and Il10 -/- Calca -/- (DKO) were cocultured at indicated ratios, in the presence of 20 ng/ml M-CSF and 50 ng/ml RANKL. Osteoclast formation was evaluated by TRAP staining. Representative images (L) and quantification (M) of TRAP + multinucleated (nuclei > 3) cells. Representative of at least 3 independent experiments. Bar indicates mean, one-way ANOVA, ∗∗P<0.01, ∗∗∗P<0.001, ∗∗∗∗P<0.0001. (N) Flow cytometry analysis of peripheral blood ILC2s in healthy donors (n=27) compared to patients with osteoporosis (n=17). T-test, ∗P<0.05. (O) Pearson correlation analysis between ILC2s and clinical samples with available BMD T-score, n=24, black indicates healthy donor, red indicates osteoporosis patients.
Rabbit Anti Cgrp A 24112, supplied by ImmunoStar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B1+cgrp/10__1523_slash_eneuro__0383___21__2021-109-23-25?v=ImmunoStar+inc
Average 90 stars, based on 1 article reviews
rabbit anti-cgrp-a 24112 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
primary antibodies directed against calcitonin gene-related peptide (cgrp)  (Enzo Biochem)
90
Enzo Biochem primary antibodies directed against calcitonin gene-related peptide (cgrp)
(A) Schematics of the experiment. Rag1 -/- female mice received daily subcutaneous injections of low-dose IL-2 (30,000 I.U.) or PBS for 4 weeks, 4 weeks after ovariectomy or sham operation. (B) Representative 3D μCT images of the distal femurs. (C) Quantification of μCT images by BV/TV (bone volume per tissue volume), Tb.N (trabecular number), Tb.Sp (trabecular separation), and Tb.Th (trabecular thickness), n=7-10 per group, bar indicates mean, one-way ANOVA, ∗P<0.05, ∗∗P<0.01. (D) Representative histological images of bone sections stained with H&E (top), TRAP (middle), and anti-TRAP immunohistochemistry (bottom) to evaluate the abundance of osteoclasts on bone surface. (E) UMAP visualization of bone marrow innate lymphoid cell (ILC) subsets from scRNA-seq data (Left) with key genes identifying ILC2s and ILC1s/ILC3s subclusters (Right). (F) Split UMAP visualization showing the distribution of bone marrow ILCs in each treatment group. (G) Pie charts showing the ratio of ILC2s to ILC1s/ILC3s. (H-I) Representative flow cytometry plots (H) and the quantification of BM-ILC2s (Lin - CD45 + CD127 + ST2 + Sca-1 + ) in WT and Rag1 -/- mice (I) . (J) Volcano plot of bulk RNA-seq data from purified ILC2s showing differential expression between control and IL-2 treated groups. (K) GO Pathway enrichment analysis of ILC2s comparing OVX vs. OVX + IL-2 groups from scRNA-seq data. (L-M) FACS sorted bone marrow CD3 - B220 - NK1.1 - CD11b + cells and ILC2s (Lin - CD45 + CD127 + Sca-1 + ST2 + ) from WT, Il10 -/- , <t>Calca</t> -/- and Il10 -/- Calca -/- (DKO) were cocultured at indicated ratios, in the presence of 20 ng/ml M-CSF and 50 ng/ml RANKL. Osteoclast formation was evaluated by TRAP staining. Representative images (L) and quantification (M) of TRAP + multinucleated (nuclei > 3) cells. Representative of at least 3 independent experiments. Bar indicates mean, one-way ANOVA, ∗∗P<0.01, ∗∗∗P<0.001, ∗∗∗∗P<0.0001. (N) Flow cytometry analysis of peripheral blood ILC2s in healthy donors (n=27) compared to patients with osteoporosis (n=17). T-test, ∗P<0.05. (O) Pearson correlation analysis between ILC2s and clinical samples with available BMD T-score, n=24, black indicates healthy donor, red indicates osteoporosis patients.
Primary Antibodies Directed Against Calcitonin Gene Related Peptide (Cgrp), supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B1+cgrp/pm33752736-113-25-55?v=Enzo+Biochem
Average 90 stars, based on 1 article reviews
primary antibodies directed against calcitonin gene-related peptide (cgrp) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
tyr- α -cgrp(23–37)  (Bachem)
90
Bachem tyr- α -cgrp(23–37)
(A) Schematics of the experiment. Rag1 -/- female mice received daily subcutaneous injections of low-dose IL-2 (30,000 I.U.) or PBS for 4 weeks, 4 weeks after ovariectomy or sham operation. (B) Representative 3D μCT images of the distal femurs. (C) Quantification of μCT images by BV/TV (bone volume per tissue volume), Tb.N (trabecular number), Tb.Sp (trabecular separation), and Tb.Th (trabecular thickness), n=7-10 per group, bar indicates mean, one-way ANOVA, ∗P<0.05, ∗∗P<0.01. (D) Representative histological images of bone sections stained with H&E (top), TRAP (middle), and anti-TRAP immunohistochemistry (bottom) to evaluate the abundance of osteoclasts on bone surface. (E) UMAP visualization of bone marrow innate lymphoid cell (ILC) subsets from scRNA-seq data (Left) with key genes identifying ILC2s and ILC1s/ILC3s subclusters (Right). (F) Split UMAP visualization showing the distribution of bone marrow ILCs in each treatment group. (G) Pie charts showing the ratio of ILC2s to ILC1s/ILC3s. (H-I) Representative flow cytometry plots (H) and the quantification of BM-ILC2s (Lin - CD45 + CD127 + ST2 + Sca-1 + ) in WT and Rag1 -/- mice (I) . (J) Volcano plot of bulk RNA-seq data from purified ILC2s showing differential expression between control and IL-2 treated groups. (K) GO Pathway enrichment analysis of ILC2s comparing OVX vs. OVX + IL-2 groups from scRNA-seq data. (L-M) FACS sorted bone marrow CD3 - B220 - NK1.1 - CD11b + cells and ILC2s (Lin - CD45 + CD127 + Sca-1 + ST2 + ) from WT, Il10 -/- , <t>Calca</t> -/- and Il10 -/- Calca -/- (DKO) were cocultured at indicated ratios, in the presence of 20 ng/ml M-CSF and 50 ng/ml RANKL. Osteoclast formation was evaluated by TRAP staining. Representative images (L) and quantification (M) of TRAP + multinucleated (nuclei > 3) cells. Representative of at least 3 independent experiments. Bar indicates mean, one-way ANOVA, ∗∗P<0.01, ∗∗∗P<0.001, ∗∗∗∗P<0.0001. (N) Flow cytometry analysis of peripheral blood ILC2s in healthy donors (n=27) compared to patients with osteoporosis (n=17). T-test, ∗P<0.05. (O) Pearson correlation analysis between ILC2s and clinical samples with available BMD T-score, n=24, black indicates healthy donor, red indicates osteoporosis patients.
Tyr α Cgrp(23–37), supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/%CE%B1+cgrp/pmc01978437-168-62-66?v=Bachem
Average 90 stars, based on 1 article reviews
tyr- α -cgrp(23–37) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


(A) Schematics of the experiment. Rag1 -/- female mice received daily subcutaneous injections of low-dose IL-2 (30,000 I.U.) or PBS for 4 weeks, 4 weeks after ovariectomy or sham operation. (B) Representative 3D μCT images of the distal femurs. (C) Quantification of μCT images by BV/TV (bone volume per tissue volume), Tb.N (trabecular number), Tb.Sp (trabecular separation), and Tb.Th (trabecular thickness), n=7-10 per group, bar indicates mean, one-way ANOVA, ∗P<0.05, ∗∗P<0.01. (D) Representative histological images of bone sections stained with H&E (top), TRAP (middle), and anti-TRAP immunohistochemistry (bottom) to evaluate the abundance of osteoclasts on bone surface. (E) UMAP visualization of bone marrow innate lymphoid cell (ILC) subsets from scRNA-seq data (Left) with key genes identifying ILC2s and ILC1s/ILC3s subclusters (Right). (F) Split UMAP visualization showing the distribution of bone marrow ILCs in each treatment group. (G) Pie charts showing the ratio of ILC2s to ILC1s/ILC3s. (H-I) Representative flow cytometry plots (H) and the quantification of BM-ILC2s (Lin - CD45 + CD127 + ST2 + Sca-1 + ) in WT and Rag1 -/- mice (I) . (J) Volcano plot of bulk RNA-seq data from purified ILC2s showing differential expression between control and IL-2 treated groups. (K) GO Pathway enrichment analysis of ILC2s comparing OVX vs. OVX + IL-2 groups from scRNA-seq data. (L-M) FACS sorted bone marrow CD3 - B220 - NK1.1 - CD11b + cells and ILC2s (Lin - CD45 + CD127 + Sca-1 + ST2 + ) from WT, Il10 -/- , Calca -/- and Il10 -/- Calca -/- (DKO) were cocultured at indicated ratios, in the presence of 20 ng/ml M-CSF and 50 ng/ml RANKL. Osteoclast formation was evaluated by TRAP staining. Representative images (L) and quantification (M) of TRAP + multinucleated (nuclei > 3) cells. Representative of at least 3 independent experiments. Bar indicates mean, one-way ANOVA, ∗∗P<0.01, ∗∗∗P<0.001, ∗∗∗∗P<0.0001. (N) Flow cytometry analysis of peripheral blood ILC2s in healthy donors (n=27) compared to patients with osteoporosis (n=17). T-test, ∗P<0.05. (O) Pearson correlation analysis between ILC2s and clinical samples with available BMD T-score, n=24, black indicates healthy donor, red indicates osteoporosis patients.

Journal: bioRxiv

Article Title: Therapeutic interleukin-2 rewires skeletal-immune circuits to reverse postmenopausal bone loss

doi: 10.64898/2026.01.07.696511

Figure Lengend Snippet: (A) Schematics of the experiment. Rag1 -/- female mice received daily subcutaneous injections of low-dose IL-2 (30,000 I.U.) or PBS for 4 weeks, 4 weeks after ovariectomy or sham operation. (B) Representative 3D μCT images of the distal femurs. (C) Quantification of μCT images by BV/TV (bone volume per tissue volume), Tb.N (trabecular number), Tb.Sp (trabecular separation), and Tb.Th (trabecular thickness), n=7-10 per group, bar indicates mean, one-way ANOVA, ∗P<0.05, ∗∗P<0.01. (D) Representative histological images of bone sections stained with H&E (top), TRAP (middle), and anti-TRAP immunohistochemistry (bottom) to evaluate the abundance of osteoclasts on bone surface. (E) UMAP visualization of bone marrow innate lymphoid cell (ILC) subsets from scRNA-seq data (Left) with key genes identifying ILC2s and ILC1s/ILC3s subclusters (Right). (F) Split UMAP visualization showing the distribution of bone marrow ILCs in each treatment group. (G) Pie charts showing the ratio of ILC2s to ILC1s/ILC3s. (H-I) Representative flow cytometry plots (H) and the quantification of BM-ILC2s (Lin - CD45 + CD127 + ST2 + Sca-1 + ) in WT and Rag1 -/- mice (I) . (J) Volcano plot of bulk RNA-seq data from purified ILC2s showing differential expression between control and IL-2 treated groups. (K) GO Pathway enrichment analysis of ILC2s comparing OVX vs. OVX + IL-2 groups from scRNA-seq data. (L-M) FACS sorted bone marrow CD3 - B220 - NK1.1 - CD11b + cells and ILC2s (Lin - CD45 + CD127 + Sca-1 + ST2 + ) from WT, Il10 -/- , Calca -/- and Il10 -/- Calca -/- (DKO) were cocultured at indicated ratios, in the presence of 20 ng/ml M-CSF and 50 ng/ml RANKL. Osteoclast formation was evaluated by TRAP staining. Representative images (L) and quantification (M) of TRAP + multinucleated (nuclei > 3) cells. Representative of at least 3 independent experiments. Bar indicates mean, one-way ANOVA, ∗∗P<0.01, ∗∗∗P<0.001, ∗∗∗∗P<0.0001. (N) Flow cytometry analysis of peripheral blood ILC2s in healthy donors (n=27) compared to patients with osteoporosis (n=17). T-test, ∗P<0.05. (O) Pearson correlation analysis between ILC2s and clinical samples with available BMD T-score, n=24, black indicates healthy donor, red indicates osteoporosis patients.

Article Snippet: The concentrations of IL-10 and CGRP in cultured ILC2 supernatants were measured using mouse IL-10 ELISA Kit (Biolegend) and CGRP ELISA kit (Boster), according to the manufacturer’s instruction.

Techniques: Staining, Immunohistochemistry, Flow Cytometry, RNA Sequencing, Purification, Quantitative Proteomics, Control